Show simple item record

dc.contributor.authorLiao, Hsin-Wei
dc.contributor.authorHsu, Jung-Mao
dc.contributor.authorXia, Weiya
dc.contributor.authorWang, Hung-Ling
dc.contributor.authorWang, Ying-Nai
dc.contributor.authorChang, Wei-Chao
dc.contributor.authorArold, Stefan T.
dc.contributor.authorChou, Chao-Kai
dc.contributor.authorTsou, Pei-Hsiang
dc.contributor.authorYamaguchi, Hirohito
dc.contributor.authorFang, Yueh-Fu
dc.contributor.authorLee, Hong-Jen
dc.contributor.authorLee, Heng-Huan
dc.contributor.authorTai, Shyh-Kuan
dc.contributor.authorYang, Mhu-Hwa
dc.contributor.authorMorelli, Maria P.
dc.contributor.authorSen, Malabika
dc.contributor.authorLadbury, John E.
dc.contributor.authorChen, Chung-Hsuan
dc.contributor.authorGrandis, Jennifer R.
dc.contributor.authorKopetz, Scott
dc.contributor.authorHung, Mien-Chie
dc.date.accessioned2016-02-28T05:50:29Z
dc.date.available2016-02-28T05:50:29Z
dc.date.issued2015-11-16
dc.identifier.citationLiao H-W, Hsu J-M, Xia W, Wang H-L, Wang Y-N, et al. (2015) PRMT1-mediated methylation of the EGF receptor regulates signaling and cetuximab response. Journal of Clinical Investigation 125: 4529–4543. Available: http://dx.doi.org/10.1172/JCI82826.
dc.identifier.issn0021-9738
dc.identifier.issn1558-8238
dc.identifier.pmid26571401
dc.identifier.doi10.1172/JCI82826
dc.identifier.urihttp://hdl.handle.net/10754/599404
dc.description.abstractPosttranslational modifications to the intracellular domain of the EGFR are known to regulate EGFR functions; however, modifications to the extracellular domain and their effects remain relatively unexplored. Here, we determined that methylation at R198 and R200 of the EGFR extracellular domain by protein arginine methyltransferase 1 (PRMT1) enhances binding to EGF and subsequent receptor dimerization and signaling activation. In a mouse orthotopic colorectal cancer xenograft model, expression of a methylation-defective EGFR reduced tumor growth. Moreover, increased EGFR methylation sustained signaling activation and cell proliferation in the presence of the therapeutic EGFR monoclonal antibody cetuximab. In colorectal cancer patients, EGFR methylation level also correlated with a higher recurrence rate after cetuximab treatment and reduced overall survival. Together, these data indicate that R198/R200 methylation of the EGFR plays an important role in regulating EGFR functionality and resistance to cetuximab treatment.
dc.description.sponsorshipWe thank Jennifer L. Hsu for critical reading of the manuscript; Su Zhang, Jian-Guang Shi, Zhen-Bo Han, and Jin-Fong Lee for technical assistance; Zhen Fan for providing GEO and HT29 colorectal cancer cell line; Xiangbo Wan for providing patient samples; The National Cancer Institute for providing colorectal tissue microarrays; The Cancer Center Support Grant–funded (CA016672) Characterized Cell Line Core for performing STR DNA fingerprinting; and ShRNA/ORFeome Core Facility for providing shRNA constructs. Funding was provided by NIH (CA109311, CA099031, and CCSG CA16672 to M.C. Hung; P50CA097190 to J.R. Grandis); Cancer Prevention and Research Institute of Texas (RP150245); The University of Texas MD Anderson-China Medical University and Hospital Sister Institution Fund (to M.C. Hung); Ministry of Science and Technology, International Research-intensive Centers of Excellence in Taiwan (I-RiCE; MOST 104-2911-I-002-302); Ministry of Health and Welfare, China Medical University Hospital Cancer Research Center of Excellence (MOHW104-TDU-B-212-124-002); Center for Biological Pathways; and the American Cancer Society (to J.R. Grandis). Research by S.T. Arold reported in this publication was supported by KAUST.
dc.publisherAmerican Society for Clinical Investigation
dc.titlePRMT1-mediated methylation of the EGF receptor regulates signaling and cetuximab response
dc.typeArticle
dc.contributor.departmentBiological and Environmental Sciences and Engineering (BESE) Division
dc.contributor.departmentBioscience Program
dc.contributor.departmentComputational Bioscience Research Center (CBRC)
dc.identifier.journalJournal of Clinical Investigation
dc.identifier.pmcidPMC4665782
dc.contributor.institutionUniversity of Texas M. D. Anderson Cancer Center, Houston, United States
dc.contributor.institutionUniversity of Texas Graduate School of Biomedical Sciences at Houston, Houston, United States
dc.contributor.institutionChina Medical University Taichung, Taichung, Taiwan
dc.contributor.institutionAsia University Taiwan, Wufong, Taiwan
dc.contributor.institutionKing Abdullah University of Science and Technology, Jeddah, Saudi Arabia
dc.contributor.institutionChang Gung Memorial Hospital, Taipei, Taiwan
dc.contributor.institutionVeterans General Hospital-Taipei, Taipei, Taiwan
dc.contributor.institutionNational Yang-Ming University Taiwan, Taipei, Taiwan
dc.contributor.institutionUniversity of Pittsburgh Medical Center, Pittsburgh, United States
dc.contributor.institutionUniversity of Leeds, Leeds, United Kingdom
dc.contributor.institutionGenomics Research Center, Academia Sinica, Nankang, Taiwan
dc.contributor.institutionUniversity of California, San Francisco, San Francisco, United States
kaust.personArold, Stefan T.


This item appears in the following Collection(s)

Show simple item record